Psychotropic drug treatment, clinical characteristics and cognitive processing speed in patients with schizophrenia: Results from the ELAN study

Pharmacopsychiatry

Volumn 45, Issue 4, 2012, Pages 138-145

  Frasch, K ^a   Weiser, P ^a   Becker, T ^a   Langle G ^b,d   Steinert, T ^a   Niederreiner, C ^a   Pfiffner, C ^a   Jager S ^a   Bayer, W ^c   Eschweiler, G W ^d   Kilian, R ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Abteilung Versorgungsforschung   (Germany)

^c Zentrum für Psychiatrie Die Weissenau ^*  (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

cognition; longitudinal study; medication, polypharmacy; psychotropic drug combinations; schizoaffective disorder; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERAZINE; PERPHENAZINE; PIPAMPERONE; PROMETHAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SERTINDOLE; TRANQUILIZER; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT INDICATION; WECHSLER INTELLIGENCE SCALE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862563834     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1297260     Document Type: Article

References (66)

1. Braff D L, Heaton R, Kuck J et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry: 1991; 48 891 898
2. Hill S K, Schuepbach D, Herbener E S et al. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr Res: 2004; 68 49 63 (Pubitemid 38368136)
3. Saykin A J, Gur R C, Gur R E et al. Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Arch Gen Psychiatry: 1991; 48 618 624
4. Saykin A J, Shtasel D L, Gur R E et al. Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch Gen Psychiatry: 1994; 51 124 131
5. Green M F, Kern R S, Braff D L et al. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuffo"? Schizophr Bull. 2000; 26 119 136
6. Keefe R S, Bilder R M, Davis S M et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry: 2007; 64 633 647 (Pubitemid 46878665)
7. Meltzer H Y, McGurk S R. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull: 1999; 25 233 255 (Pubitemid 29272503)
8. Velligan D I, Newcomer J, Pultz J. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res: 2002; 53 239 248 (Pubitemid 34008588)
9. Velligan D I, Mahurin R K, Diamond P L et al. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res: 1997; 25 21 31 (Pubitemid 27239627)
10. Albus M, Hubmann W, Mohr F et al. Neurocognitive functioning in patients with first-episode schizophrenia. Results of a prospective 5-year follow-up study. Eur Arch Psychiatry: 2006; 256 442 451 (Pubitemid 44584061)
11. Bilder R M, Goldman R S, Robinson D et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry: 2000; 157 549 559 (Pubitemid 30191193)
12. Censits D M, Ragland J D, Gur R C et al. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res: 1997; 24 289 298 (Pubitemid 27163240)
13. Heydebrand G, Weiser M, Rabinowitz J et al. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res: 2004; 68 1 9 (Pubitemid 38368131)
14. Hoff A L, Harris D, Faustman W O et al. A neuropsychological study of early onset schizophrenia. Schizophr Res: 1996; 20 21 28 (Pubitemid 26387501)
15. Rund B R, Melle I, Friis S et al. Neurocognitive dysfunction in first-episode psychosis: Correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry: 2004; 161 466 472 (Pubitemid 38326101)
16. Schuepbach D, Keshavan M S, Kmiec J A et al. Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophr Res: 2002; 53 249 261 (Pubitemid 34008589)
17. Albus M, Hubmann W, Scherer J et al. A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci: 2002; 252 262 267 (Pubitemid 36227530)
18. Hoff A L, Sakuma M, Wieneke M et al. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry: 1999; 156 1336 1341 (Pubitemid 29416528)
19. Rund B R, Melle I, Friis S et al. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr Res: 2007; 91 132 140
20. Davidson M, Galderisi S, Weiser M et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST). Am J Psychiatry: 2009; 166 675 682
21. Woodward N D, Purdon S E, Meltzer H Y et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res: 2007; 89 211 224 (Pubitemid 44881296)
22. Singh M, Kay S. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia: theoretical implications for potency differences among neuroleptics. Psychopharmacol: 1975; 43 103 113
23. Woodward N D, Purdon S E, Meltzer H Y et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharm: 2005; 8 457 472 (Pubitemid 41002500)
24. Green M F, Marshall BD J, Wirshing W C et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry: 1997; 154 799 804 (Pubitemid 27230102)
25. Purdon S, Jones BD W, Stip E et al. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry: 2000; 57 249 258 (Pubitemid 30140434)
26. Sebastian C S, Glazer W, Buckley P F. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem: 2004; 11 329 342 (Pubitemid 38240210)
27. Cheer S M, Wagstaff A J. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs: 2004; 18 173 199 (Pubitemid 38293801)
28. Nasrallah H A, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry: 2002; 63 13 12 20 (Pubitemid 35471365)
29. Sax K W, Strakowski S M, Keck P E. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res: 1998; 33 151 155 (Pubitemid 28446539)
30. Lerner V, Chudakova B, Kravets S et al. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol: 2000; 23 284 286 (Pubitemid 32014479)
31. Procyshyn R M, Honer W G, Wu TK Y et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry: 2010; 71 566 573
32. Zink M, Englisch S, Mayer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opinion Psychiatry: 2010; 23 103 111
33. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: A systematic review. Schizophr Res: 2009; 113 1 11
34. Centorrino F, Goren J L, Hennen J et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry: 2004; 161 700 706 (Pubitemid 38445515)
35. Chakos M H, Glick I D, Miller A L et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv: 2006; 57 1094 1101 (Pubitemid 44204901)
36. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev: 2009; 3: CD006324
37. Correll C U, Rummel-Kluge C, Corves C et al. Antipsychotic combinations vs. monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr Bull: 2009; 35 443 457
38. Pandurangi A K, Dalkilic A. Polypharmacy with second-generation antipsychotics: A review of evidence. J Psychiatr Pract: 2008; 14 345 367
39. Wobrock T, Falkai P. Combination therapy in the treatment of schizophrenia beyond polypharmacy. J Neurol Neurochir Psychiatr: 2008; 9 32 38
40. Anghelescu I, Szegedi A, Schlegel S et al. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. Eur Neuropsychopharmacol: 1998; 8 315 320 (Pubitemid 28557027)
41. Tiihonen J, Hallikainen T, Ryynänen O P et al. Lamotrigine in therapy-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry: 2003; 54 1241 1248 (Pubitemid 37464870)
42. Johns C A, Thompson J W. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull: 1995; 21 607 619
43. Stahl S M, Grady M M. A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. Curr Med Chem: 2004; 11 313 327 (Pubitemid 38240209)
44. Hori H, Noguchi H, Hashimoto R et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res: 2006; 86 138 146 (Pubitemid 44234045)
45. Elie D, Poirier M, Chianetta J et al. Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol: 2010; 24 1037 1044
46. Keefe R S, Goldberg T E, Harvey P D et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res: 2004; 68 283 297 (Pubitemid 38526150)
47. Kay S R, Opler L A, Lindemeyer J P. The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. Br J Psychiatry: 1989; 155 59 65 (Pubitemid 19270851)
48. American Psychiatric Association. Diagnostic and statistical manual of mental disorders Fourth Edition Text Revision. ed. Washington D C. American Psychiatric Association: 2000
49. Chisholm D, Knapp M, Knudsen H C et al. Client Sociodemographic and Service Receipt Inventory European Version. Br J Psychiatry: 2000; 177 s28 s33
50. Andreasen N C, Pressler M, Nopoulos P et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry: 2010; 67 255 262
51. Atkins M, Burgess A, Bottomley C et al. Chlorpromazine equivalents: a consensus of opinion for both clinical and research. Psychiatr Bull: 1997; 21 224 226 (Pubitemid 27225823)
52. Gardner D M, Murphy A L, O'Donnell H et al. International consensus study of antipsychotic dosing. Am J Psychiatry: 2010; 167 686 693
53. Woods S W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry: 2003; 64 663 667 (Pubitemid 36750143)
54. Kaufman A, Lichtenberger E. Assessing adolescent and adult intelligence. Hoboken John Wiley & Sons: 2002
55. Boone D E. Reliability of the WAIS-R with psychiatric inpatients. J Clin Psychol: 1992; 48 72 76
56. Dickinson D, Ramsey M E, Gold J M. Overlooking the obvious. A meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry: 2007; 64 532 542 (Pubitemid 46718286)
57. Tewes U. HAWIE-R Hamburg-Wechsler Intelligenztest für Erwachsene Revision 1991, Handbuch und Testanweisung. Hans Huber; Bern Göttingen, Toronto, Seattle: 1994
58. D'Agostino R B. Tutorial in biostatistics. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med: 1998; 17 2265 2281
59. Kilian R, Angermeyer M C. The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trial. Qual Life Res: 2005; 14 1275 1289 (Pubitemid 40895750)
60. Swanson J M, Hinshaw S P, Arnold L E et al. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry: 2007; 46 1003 1014 (Pubitemid 47220684)
61. Greene W H. Econometric analysis. Fifth Edition ed. Upper Saddle River Prentice Hall: 2003
62. Stata Corporation. Stata statistical software: Release 10 College Station TX StataCorp LP: 2007
63. Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. 7. Auflage. Springer Heidelberg: 2009
64. Barr W B. Neuropsychological testing of high school athletes. Preliminary norms and test-retest indices. Arch Clin Neuropsychol: 2003; 18 91 101 (Pubitemid 36120397)
65. Bird C M, Papadopoulou K, Ricciardelli P et al. Monitoring cognitive changes: psychometric properties of six cognitive tests. Br J Psychol: 2004; 43 197 210 (Pubitemid 38923511)
66. Salinsky M C, Storzbach D, Dodrill C B et al. Test-retest bias, reliability, and regression equations for neuropsychological measures repeated over a 12-16-week period. J Int Neuropsychol Soc: 2001; 7 597 605 (Pubitemid 32700954)